Neuren Pharmaceuticals Ltd
NEU
Company Profile
Business description
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
Contact
117 Camberwell Road
Suite 1.01
Hawthorn East
MelbourneVIC3123
AUST: +61 390920480
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
37
Stocks News & Analysis
stocks
Chart of the Week: BHP’s valuation hits historic levels
BHP and peers are trading as if the copper boom is here to stay.
stocks
3 cheap wide moat growth stocks
4 and 5 star companies that can protect and grow their earnings.
stocks
ASX biotech expands diagnostics portfolio after FDA approval
FDA nod adds another growth driver for ASX share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,908.80 | 34.30 | 0.39% |
| CAC 40 | 8,140.59 | 50.31 | 0.62% |
| DAX 40 | 25,537.75 | 135.47 | 0.53% |
| Dow JONES (US) | 51,461.90 | 631.21 | -1.21% |
| FTSE 100 | 10,688.47 | 30.34 | 0.28% |
| HKSE | 24,476.28 | 237.50 | -0.96% |
| NASDAQ | 25,978.43 | 3.14 | -0.01% |
| Nikkei 225 | 63,966.87 | 43.87 | 0.07% |
| NZX 50 Index | 13,735.73 | 113.01 | 0.83% |
| S&P 500 | 7,551.81 | 33.92 | -0.45% |
| S&P/ASX 200 | 8,730.30 | 33.80 | 0.39% |
| SSE Composite Index | 3,880.85 | 10.75 | -0.28% |